Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

Executive Summary

The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

You may also be interested in...



FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK

Short public meeting on the biosimilar user fee agreement suggests the proof will be in the scheduling.

User Fee Negotiations: Should Consumer Stakeholders Sit At Table With Industry, FDA?

While FDA provided unprecedented access during PDUFA V talks, groups still want to help negotiate, which an expert thinks would irk industry.

FDA, Industry Reach Agreement On Major Portions Of Generic User Fee Program

Pending agreement includes a one-time fee for ANDA applications in the backlog.

Related Content

Topics

UsernamePublicRestriction

Register

PS053122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel